1. Celgene Corporation, Summit, NJ;
2. Celgene Institute for Translational Research Europe, Celgene Corporation, Seville, Spain;
3. IUC-Oncopole and Cancer Research Center of Toulouse, INSERM U1037, Toulouse, France;
4. Myeloma Unit, University of Torino, Torino, Italy;
5. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;
6. Hematology Department, University Hospital of Salamanca, Institute for Biomedical Research (IBSAL), Salamanca, Spain;
7. Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain;
8. Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain;
9. University Hospital Heidelberg, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; and
10. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands